249 related articles for article (PubMed ID: 19432794)
1. Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning.
Islam MR; Shioya K; Nagao J; Nishie M; Jikuya H; Zendo T; Nakayama J; Sonomoto K
Mol Microbiol; 2009 Jun; 72(6):1438-47. PubMed ID: 19432794
[TBL] [Abstract][Full Text] [Related]
2. Mapping and identification of the region and secondary structure required for the maturation of the nukacin ISK-1 prepeptide.
Nagao J; Morinaga Y; Islam MR; Asaduzzaman SM; Aso Y; Nakayama J; Sonomoto K
Peptides; 2009 Aug; 30(8):1412-20. PubMed ID: 19481127
[TBL] [Abstract][Full Text] [Related]
3. Ring A of nukacin ISK-1: a lipid II-binding motif for type-A(II) lantibiotic.
Islam MR; Nishie M; Nagao J; Zendo T; Keller S; Nakayama J; Kohda D; Sahl HG; Sonomoto K
J Am Chem Soc; 2012 Feb; 134(8):3687-90. PubMed ID: 22329487
[TBL] [Abstract][Full Text] [Related]
4. Lantibiotic engineering: molecular characterization and exploitation of lantibiotic-synthesizing enzymes for peptide engineering.
Nagao J; Aso Y; Shioya K; Nakayama J; Sonomoto K
J Mol Microbiol Biotechnol; 2007; 13(4):235-42. PubMed ID: 17827974
[TBL] [Abstract][Full Text] [Related]
5. Lysine-oriented charges trigger the membrane binding and activity of nukacin ISK-1.
Asaduzzaman SM; Nagao J; Aso Y; Nakayama J; Sonomoto K
Appl Environ Microbiol; 2006 Sep; 72(9):6012-7. PubMed ID: 16957223
[TBL] [Abstract][Full Text] [Related]
6. Characterization of functional domains of lantibiotic-binding immunity protein, NukH, from Staphylococcus warneri ISK-1.
Okuda K; Aso Y; Nagao J; Shioya K; Kanemasa Y; Nakayama J; Sonomoto K
FEMS Microbiol Lett; 2005 Sep; 250(1):19-25. PubMed ID: 16009508
[TBL] [Abstract][Full Text] [Related]
7. Binding specificity of the lantibiotic-binding immunity protein NukH.
Okuda K; Yanagihara S; Shioya K; Harada Y; Nagao J; Aso Y; Zendo T; Nakayama J; Sonomoto K
Appl Environ Microbiol; 2008 Dec; 74(24):7613-9. PubMed ID: 18978082
[TBL] [Abstract][Full Text] [Related]
8. Effect of replacing glutamic residues upon the biological activity and stability of the circular enterocin AS-48.
Sánchez-Hidalgo M; Martínez-Bueno M; Fernández-Escamilla AM; Valdivia E; Serrano L; Maqueda M
J Antimicrob Chemother; 2008 Jun; 61(6):1256-65. PubMed ID: 18385141
[TBL] [Abstract][Full Text] [Related]
9. Characterization of modification enzyme NukM and engineering of a novel thioether bridge in lantibiotic nukacin ISK-1.
Shioya K; Harada Y; Nagao J; Nakayama J; Sonomoto K
Appl Microbiol Biotechnol; 2010 Apr; 86(3):891-9. PubMed ID: 19915831
[TBL] [Abstract][Full Text] [Related]
10. Description of complete DNA sequence of two plasmids from the nukacin ISK-1 producer, Staphylococcus warneri ISK-1.
Aso Y; Koga H; Sashihara T; Nagao J; Kanemasa Y; Nakayama J; Sonomoto K
Plasmid; 2005 Mar; 53(2):164-78. PubMed ID: 15737403
[TBL] [Abstract][Full Text] [Related]
11. The biology of lantibiotics from the lacticin 481 group is coming of age.
Dufour A; Hindré T; Haras D; Le Pennec JP
FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664
[TBL] [Abstract][Full Text] [Related]
12. Nukacin 3299, a lantibiotic produced by Staphylococcus simulans 3299 identical to nukacin ISK-1.
Ceotto H; Holo H; da Costa KF; Nascimento Jdos S; Salehian Z; Nes IF; Bastos Mdo C
Vet Microbiol; 2010 Nov; 146(1-2):124-31. PubMed ID: 20627619
[TBL] [Abstract][Full Text] [Related]
13. Determination of essential and variable residues in pediocin PA-1 by NNK scanning.
Tominaga T; Hatakeyama Y
Appl Environ Microbiol; 2006 Feb; 72(2):1141-7. PubMed ID: 16461660
[TBL] [Abstract][Full Text] [Related]
14. Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design.
Cotter PD; Deegan LH; Lawton EM; Draper LA; O'Connor PM; Hill C; Ross RP
Mol Microbiol; 2006 Nov; 62(3):735-47. PubMed ID: 17076667
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a gene cluster of Staphylococcus warneri ISK-1 encoding the biosynthesis of and immunity to the lantibiotic, nukacin ISK-1.
Aso Y; Sashihara T; Nagao J; Kanemasa Y; Koga H; Hashimoto T; Higuchi T; Adachi A; Nomiyama H; Ishizaki A; Nakayama J; Sonomoto K
Biosci Biotechnol Biochem; 2004 Aug; 68(8):1663-71. PubMed ID: 15322349
[TBL] [Abstract][Full Text] [Related]
16. Enhanced production of nukacin D13E in Lactococcus lactis NZ9000 by the additional expression of immunity genes.
Puramattathu TV; Islam MR; Nishie M; Yanagihara S; Nagao J; Okuda K; Zendo T; Nakayama J; Sonomoto K
Appl Microbiol Biotechnol; 2012 Jan; 93(2):671-8. PubMed ID: 21904816
[TBL] [Abstract][Full Text] [Related]
17. LiaRS reporter assay: A simple tool to identify lipid II binding moieties in lantibiotic nukacin ISK-1.
Elsayed KM; Islam MR; Abdullah-Al-Mahin ; Nagao JI; Zendo T; Sonomoto K
J Biosci Bioeng; 2017 Mar; 123(3):398-401. PubMed ID: 27856233
[TBL] [Abstract][Full Text] [Related]
18. Generation of an actagardine A variant library through saturation mutagenesis.
Boakes S; Ayala T; Herman M; Appleyard AN; Dawson MJ; Cortés J
Appl Microbiol Biotechnol; 2012 Sep; 95(6):1509-17. PubMed ID: 22526797
[TBL] [Abstract][Full Text] [Related]
19. A novel lantibiotic, nukacin ISK-1, of Staphylococcus warneri ISK-1: cloning of the structural gene and identification of the structure.
Sashihara T; Kimura H; Higuchi T; Adachi A; Matsusaki H; Sonomoto K; Ishizaki A
Biosci Biotechnol Biochem; 2000 Nov; 64(11):2420-8. PubMed ID: 11193411
[TBL] [Abstract][Full Text] [Related]
20. Bactericidal activity of nukacin ISK-1: an alternative mode of action.
Roy U; Islam MR; Nagao J; Iida H; Mahin AA; Li M; Zendo T; Nakayama J; Sonomoto K
Biosci Biotechnol Biochem; 2014; 78(7):1270-3. PubMed ID: 25229869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
